Facebook
Twitter
LinkedIn
Forward
Brain Metastases Radiotherapy While Mitigating Radionecrosis and Neurotoxicity in a Community Setting
There are many strategies for managing brain mets with radiotherapy. With increasing access to technology and the expanding multidisciplinary care of patients, failure to stay informed of the management options for tailored brain metastases and toxicity management leads to lower quality of care by practicing clinicians for our patients.
This activity is divided into 3 sections: 1) Updates on brain mets management: Discussion of selecting patients for HA-WBRT and SRS including a good amount of discussion on developing concepts in pre- and post-op radiosurgery (who to consider for what sequence, dose and planning considerations, etc). 2) Neurocognitive preservation: What does it actually mean to patients (tips on counseling, supportive resources), differences with SRS vs. whole brain, memantine (role, considerations when prescribing, taper and other), hippocampal avoidance (how to and planning), and role for additional substructure sparing. 3) Radionecrosis: Prevention strategies for intact brain mets (dose/fraction, technique/platform considerations, composite dosing or serial treatment days), diagnosis tools (PET, rCBV), and management (Avastin, LITT, excision, etc).
Topics:
- Tailored Approach to Brain Metastases Management
Stuart H. Burri, MD - Neurotoxicity After Brain Metastasis Radiotherapy
William Breen, MD - Prevention and Management Strategies for Radionecrosis
Raj Singh, MD - Q and A
Beant Singh Gill, MD - Moderator
Full Panel
This activity is available from February 25, 2025, through 11:59 p.m. Eastern time on February 24, 2027.
The content was originally presented and recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, surgeons, nurses, radiation dosimetrists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Develop a framework for selecting the optimal treatment for patients with brain metastases.
- Increase the tools for diagnosis and management of radionecrosis.
- Best counsel patients on risk of neurotoxicity and options for mitigating and managing the toxicity.
- Avani Dholakia Rao, MD, is employed by Radiation Oncology Associates of the National Capital Region.
- Stuart H. Burri, MD, is employed by Southeast Radiation Oncology Group. Dr. Burri is President and partner of the Southeast Radiation Oncology Group. Dr. Burri has ownership equity in Radiation Oncology Centers of the Carolinas (ROCC), Charlotte Physics Holding (CPH), FUSE Oncology Holding and Oncology Practice Solutions (OPS). Dr. Burri serves an uncompensated role as Chairman of Radiation Oncology with Atrium Health – Levine Cancer Institute.
- William Breen, MD, is employed by Mayo Clinic Rochester.
- Raj Singh, MD, is employed by The Ohio State University Comprehensive Cancer Center.
- Beant Singh Gill, MD, is employed by Associates in Radiation Medicine and Luminis Health. Dr. Gill is a Partner and holds ownership equity in Associates in Radiation Medicine. Dr. Gill serves in an uncompensated faculty role with George Washington University. Dr. Gill serves in uncompensated roles with Chesapeake Potomac Regional Cancer Center (Medical Director), the American College of Radiology (CAC representative) and Associates in Radiation Medicine (President).
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until February 24, 2027, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.